A new trading day began on Friday, with Y-Mabs Therapeutics Inc (NASDAQ: YMAB) stock price down -6.77% from the previous day of trading, before settling in for the closing price of $7.39. YMAB’s price has ranged from $6.92 to $20.90 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 46.29% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged -27.74%. With a float of $37.22 million, this company’s outstanding shares have now reached $44.77 million.
In an organization with 100 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 88.83%, operating margin of -33.66%, and the pretax margin is -27.28%.
Y-Mabs Therapeutics Inc (YMAB) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Y-Mabs Therapeutics Inc is 16.91%, while institutional ownership is 60.21%. The most recent insider transaction that took place on Sep 13 ’24, was worth 875,550. In this transaction CHIEF BUSINESS OFFICER of this company sold 65,000 shares at a rate of $13.47, taking the stock ownership to the 97,681 shares. Before that another transaction happened on Sep 16 ’24, when Company’s CHIEF BUSINESS OFFICER sold 30,000 for $12.97, making the entire transaction worth $389,100. This insider now owns 67,681 shares in total.
Y-Mabs Therapeutics Inc (YMAB) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.15 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -27.74% per share during the next fiscal year.
Y-Mabs Therapeutics Inc (NASDAQ: YMAB) Trading Performance Indicators
Here are Y-Mabs Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.54. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.65.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.54, a number that is poised to hit -0.10 in the next quarter and is forecasted to reach -0.58 in one year’s time.
Technical Analysis of Y-Mabs Therapeutics Inc (YMAB)
Let’s dig in a bit further. During the last 5-days, its volume was 0.35 million. That was inferior than the volume of 0.35 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 2.13%. Additionally, its Average True Range was 0.60.
During the past 100 days, Y-Mabs Therapeutics Inc’s (YMAB) raw stochastic average was set at 0.54%, which indicates a significant decrease from 2.34% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 38.42% in the past 14 days, which was lower than the 62.90% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.79, while its 200-day Moving Average is $12.68. However, in the short run, Y-Mabs Therapeutics Inc’s stock first resistance to watch stands at $7.23. Second resistance stands at $7.58. The third major resistance level sits at $7.77. If the price goes on to break the first support level at $6.69, it is likely to go to the next support level at $6.50. Assuming the price breaks the second support level, the third support level stands at $6.15.
Y-Mabs Therapeutics Inc (NASDAQ: YMAB) Key Stats
With a market capitalization of 308.60 million, the company has a total of 44,789K Shares Outstanding. Currently, annual sales are 84,820 K while annual income is -21,430 K. The company’s previous quarter sales were 18,460 K while its latest quarter income was -7,000 K.
